TOTUM•63 is a unique and patented combination of 5 plant extracts, designed to target a number of pathophysiological mechanisms of type 2 diabetes. Its efficacy was clinically proven in people with prediabetes.
- 14 communications at international scientific congresses since 2016, including 11 selections by the three main global diabetes congresses: American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and the International Diabetes Federation (IDF).
- 6 scientific papers published by international journals since 2021: a first set of preclinical and clinical results on TOTUM•63 published, as part of a comprehensive publication plan for this active substance.